Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07264959 · ClinicalTrials.gov registry record
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
A clinical trial, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- 150
- Enrollment target
NCT07264959 is a clinical trial that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 150 participants.
The verdict
NCT07264959 is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
Study Summary
This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2032-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07264959
The ClinicalTrials.gov registry entry for NCT07264959 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07264959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07264959 about?
NCT07264959 is a clinical study titled "An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)". This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis...
What is the current status of trial NCT07264959?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2026-04-15. Estimated completion is 2032-12-01.
Who is sponsoring clinical trial NCT07264959?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.